Pharma
Regulatory
Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation
Shots: The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology The BT […]readmore